Low Malignant Potential (LMP) Ovarian Tumor

Low malignant potential (LMP) ovarian tumor (also called a borderline ovarian tumor) is a growth that looks abnormal under the microscope but does not behave like typical cancer. It tends to grow slowly, rarely invades nearby tissues, and is much less likely to spread compared with invasive ovarian cancer. Most people do well after surgery, especially when the tumor is found early. In many cases, surgery alone is enough, and chemotherapy is not routinely needed. Cancer.gov+1

A low malignant potential (LMP) ovarian tumor—now most often called a borderline ovarian tumor (BOT)—is an epithelial tumor of the ovary that shows extra cell growth and atypia under the microscope, but does not invade nearby tissue the way true cancer does. Because there is no destructive invasion, these tumors usually have a much better outlook than invasive ovarian cancer. Most are found early (stage I) and are treated mainly with surgery. Care still matters because a small number can recur or, rarely, progress. Cancer.gov+1

Doctors diagnose and stage LMP tumors using surgery and pathology. Follow-up usually includes pelvic exams and periodic imaging; tumor markers may be used in select cases but are less reliable than in invasive disease. Fertility-sparing surgery can be considered for people who want a future pregnancy, with a plan for careful surveillance. Cancer.gov

---

Other names

• Borderline ovarian tumor (preferred, modern term)

• Tumor of low malignant potential (LMP)

• Atypical proliferative tumor (older pathology wording)
  All three describe the same general group of non-invasive epithelial ovarian tumors. bccancer.bc.ca+1

---

Types

Doctors classify borderline tumors by the cell type and by certain growth patterns seen under the microscope:

1. Serous borderline tumor (SBT) – the most common; sometimes shows a micropapillary pattern, which needs closer follow-up.

2. Mucinous borderline tumor (MBT) – can be intestinal-type or endocervical-type; these are often large cystic masses.

3. Endometrioid borderline tumor – linked to endometriosis in some patients.

4. Seromucinous (mixed) borderline tumor – shows both serous- and mucinous-like areas and often coexists with endometriosis.

5. Clear cell borderline tumor – rare.

6. Borderline tumor with microinvasion – shows tiny foci of invasion but behaves much better than invasive carcinoma; needs careful staging and follow-up.
   Pathologists sometimes add molecular notes (for example, KRAS or BRAF mutations in serous/mucinous lesions). Staging follows FIGO rules used for ovarian tumors in general. PMC+2annalsofoncology.org+2

Borderline tumors make up roughly 15–20% of epithelial ovarian tumors. They are often diagnosed younger than invasive ovarian cancer—many patients are in their 40s and 70%–75% are stage I at diagnosis. Prognosis is generally excellent after proper surgery. Cancer.gov+2bccancer.bc.ca+2

---

Possible causes

We rarely know a single “cause.” Instead, these are associations or mechanisms that may contribute. Not every patient will have any of these.

1. Ovulatory lifetime exposure – more total ovulations may increase epithelial stress and mutation chance. Fewer ovulations (pregnancy, birth control pills) may lower risk. ACOG

2. Endometriosis – especially tied to seromucinous and endometrioid borderline types. annalsofoncology.org

3. Somatic gene changes (e.g., KRAS, BRAF) – common driver mutations in serous and mucinous borderline tumors; they affect cell-growth signaling. annalsofoncology.org

4. Hormonal environment – estrogen-dominant states may stimulate target epithelium over time (mechanism proposed, not proven causation). annalsofoncology.org

5. Nulliparity (no prior births) – reflects higher ovulatory cycles and associated risk. ACOG

6. Infertility or ovulation-induction history – data are mixed; some series suggest a small increase in borderline tumors. ACOG

7. Smoking – particularly associated with mucinous ovarian tumors (including borderline). Society of Gynecologic Oncology

8. Personal history of endometrial pathology – overlaps in some borderline histologies. annalsofoncology.org

9. Pelvic inflammation – chronic irritation is a theorized promoter for epithelial change. PMC

10. Genetic susceptibility outside BRCA – classic BRCA links are weak for borderline and mucinous types; most are not BRCA-driven. Society of Gynecologic Oncology

11. Environmental exposures – unproven; studied as part of ovarian neoplasm epidemiology. PubMed

12. Obesity and metabolic factors – may shift estrogen and inflammatory pathways. annalsofoncology.org

13. Early menarche/late menopause – more ovulations across life. ACOG

14. Benign cystadenomas as precursors – stepwise change to atypical proliferative (borderline) epithelium is proposed in mucinous lesions. PMC

15. Prior pelvic surgery with residual implants – rarely, borderline-type implants can arise; association more than cause. PMC

16. Low-grade serous pathway – borderline serous tumors fit a “low-grade” pathway distinct from high-grade serous carcinoma. annalsofoncology.org

17. Ovarian cyst persistence – long-standing cystic epithelium may accumulate mutations. PMC

18. Hormone replacement therapy (HRT) – evidence mixed; any risk, if present, appears small and not clearly causal for borderline tumors. annalsofoncology.org

19. Familial non-BRCA patterns – very uncommon; most borderline tumors are sporadic. exxcellence.org

20. Field effect in Müllerian epithelium – shared biology between ovarian, tubal, and peritoneal epithelium can permit atypical proliferations without invasion. annalsofoncology.org

---

Common symptoms

1. Bloating or fullness – fluid or a large cyst can stretch the belly.

2. Lower tummy (pelvic) pain or pressure – the ovary sits low in the pelvis; a mass can press on nearby organs.

3. Belly swelling – size of the cyst or, less often, fluid (ascites).

4. Frequent urination – pressure on the bladder.

5. Early fullness while eating – pressure on the stomach area.

6. Constipation or bowel changes – pressure on the rectum or colon.

7. Irregular periods – less common, but hormonal effects or stress can alter cycles.

8. Pain with sex – pressure or pulling on pelvic structures.

9. Low back discomfort – referred pain from a pelvic mass.

10. Unexplained weight change – from a large cyst or reduced appetite.

11. Fatigue – non-specific; chronic symptoms can wear you down.

12. Palpable mass – sometimes a doctor can feel an adnexal mass on exam.

13. Nausea/indigestion – mass effect on the stomach or bowels.

14. Shortness of breath – rare, from very large masses or fluid under the diaphragm.

15. Infertility concerns – some patients learn about the mass during fertility workups.
    (These are similar to symptoms seen with many adnexal masses; borderline tumors often present earlier and behave more indolently than invasive cancer.) ACOG+1

---

Diagnostic tests

Key idea: No single blood test can diagnose a borderline tumor. Doctors use history, exam, imaging, tumor markers, and—most importantly—pathology from surgery. Staging follows FIGO rules. ACOG+2Cancer.gov+2

A) Physical examination (what the clinician sees or feels)

1. General exam and symptom review
   Your clinician asks about bloating, pain, periods, and weight change, and checks your abdomen for swelling or tenderness. This helps judge urgency and plan imaging. ACOG

2. Abdominal palpation
   Hands-on belly exam can sometimes feel a large mass or fluid. While not precise, it guides the next steps (ultrasound, labs). ACOG

B) “Manual” pelvic evaluation (hands-on gynecologic exam)

3. Speculum exam
   The speculum allows the doctor to see the cervix and vaginal walls. It doesn’t diagnose an ovarian mass directly but rules out visible cervical or vaginal causes of bleeding or pain. ACOG

4. Bimanual pelvic exam
   One hand in the vagina and one on the abdomen lets the clinician feel the uterus and adnexa. A fullness or mobile cystic mass may be noted, prompting imaging. ACOG

5. Rectovaginal exam (as needed)
   A finger in the rectum and vagina at the same time can better assess the posterior pelvis, uterosacral ligaments, and cul-de-sac for masses or nodules. ACOG

C) Laboratory & pathology (the decisive category)

6. CA-125 blood test
   This tumor marker is not specific, but in postmenopausal patients or with concerning imaging, a raised CA-125 increases suspicion. Many borderline tumors have normal or only mildly elevated CA-125. It cannot confirm cancer on its own. ACOG

7. HE4 and multivariate risk indices (e.g., ROMA)
   In some settings, HE4 helps triage an adnexal mass, but results must be read with imaging and clinical findings. Borderline tumors may not push markers very high. ACOG

8. Other markers to narrow the differential
   CEA, CA19-9, inhibin, AFP, β-hCG, and LDH can help distinguish mucinous tumors or non-epithelial masses (like germ-cell tumors) when imaging is unclear. These do not prove a borderline tumor but help rule things in or out. ACOG

9. Complete blood count & chemistry panel
   These tests check anemia, infection signs, and organ function to plan safe surgery and anesthesia. ACOG

10. Intra-operative frozen section
    During surgery, the pathologist can examine a small piece quickly to guide the extent of surgery (for example, to consider fertility-sparing steps). Frozen section is useful but not perfect; final diagnosis still relies on permanent sections. PMC

11. Definitive histopathology (permanent sections)
    This is the gold standard. The pathologist looks for epithelial proliferation and atypia without destructive stromal invasion to confirm a borderline tumor and its specific type (serous, mucinous, etc.). PMC

12. Cytology of peritoneal washings
    At staging surgery, washings look for free tumor cells in the abdominal cavity; results contribute to FIGO staging. Society of Gynecologic Oncology

13. Immunohistochemistry & molecular testing (when needed)
    Markers such as WT1, PAX8, CK7, ER/PR, and molecular profiling (e.g., KRAS/BRAF) help confirm tumor origin and subtype, especially in tricky cases. annalsofoncology.org

D) Imaging tests (to characterize the mass and stage)

14. Transvaginal ultrasound (TVUS)
    This is the first-line imaging test. It shows whether a mass is cystic, solid, or mixed, and can display septations, papillary projections, or nodules that raise concern for borderline features. Structured approaches (like IOTA rules) improve accuracy. ACOG

15. Color Doppler ultrasound
    Assesses blood flow in septa or papillary areas. Increased internal vascularity can raise suspicion and guide the surgical plan. ACOG

16. MRI of the pelvis
    MRI helps when ultrasound is uncertain. It can better show papillary excrescences, mural nodules, and the relationship to nearby organs, and it avoids radiation. ACOG

17. CT scan of abdomen/pelvis
    CT helps plan surgery for very large masses or to look for implants or lymph nodes when staging is needed. CT is commonly used in pre-operative workups. Cancer.gov

18. Chest imaging (X-ray or CT as indicated)
    Used to complete staging or evaluate symptoms. Borderline tumors rarely spread to the chest, but imaging can be appropriate in selected cases. Cancer.gov

19. PET-CT (select cases)
    PET-CT is not routine for borderline tumors but may be used if there is confusing or recurrent disease where metabolic information will change management. annalsofoncology.org

E) “Electrodiagnostic” tests (important note)

20. No electrodiagnostic test diagnoses borderline ovarian tumor
    Electrodiagnostic studies like EMG or nerve-conduction tests are not used for ovarian masses. Pre-operative ECG may be done to assess heart safety for anesthesia, but it does not help diagnose the tumor. This category is essentially not applicable for ovarian borderline tumors. annalsofoncology.org+1

Non-pharmacological treatments (therapies and other supports)

1. Shared decision-making & second opinion (gynecologic oncology)
   Description (≈150 words): Because LMP tumors often have excellent outcomes with surgery alone, treatment choices should carefully balance benefits and side effects. A consultation with a gynecologic oncologist clarifies whether conservative (fertility-sparing) surgery or more extensive surgery is best, and whether any additional therapy is needed. Getting a second opinion helps confirm the diagnosis because pathology interpretation can be challenging in borderline tumors. This collaborative process also sets up a personalized surveillance plan and clarifies warning signs to watch for.
   Purpose: Choose the least-harm, most-effective plan for your goals (cure, fertility, quality of life).
   Mechanism: Expert review of imaging, operative notes, and pathology; risk stratification; evidence-guided follow-up. Cancer.gov

2. Fertility counseling
   Description: Many people with LMP tumors are diagnosed in their reproductive years. A reproductive specialist can explain options like oocyte or embryo cryopreservation before surgery, or fertility-sparing procedures (such as unilateral salpingo-oophorectomy or cystectomy when appropriate). Counseling also covers timing of pregnancy and how future monitoring will work during and after fertility treatment.
   Purpose: Preserve the possibility of biological parenthood and plan safe timing.
   Mechanism: Aligns surgical approach and follow-up with reproductive goals while maintaining oncologic safety. Cancer.gov

3. Structured surveillance program
   Description: After surgery, most patients are followed with scheduled pelvic exams and imaging at defined intervals. Blood markers may be used selectively, but imaging and clinical review are more informative for LMP tumors. A written schedule reduces anxiety and supports early detection of rare recurrences.
   Purpose: Detect recurrence early and maintain peace of mind.
   Mechanism: Risk-adapted follow-up using exam and imaging at set time points. Cancer.gov

4. Pelvic floor physical therapy (PFPT)
   Description: Surgery can lead to pelvic pain, scar-related tightness, or dyspareunia (pain with intercourse). PFPT uses gentle manual techniques, relaxation, stretching, and home exercises to restore mobility and reduce pain. Therapists also teach bladder/bowel strategies after pelvic surgery.
   Purpose: Reduce pelvic pain and improve function and sexual comfort.
   Mechanism: Targeted myofascial release, graded exposure, and neuromuscular retraining. Cancer.gov

5. Psychosocial support & evidence-based coping (CBT/mindfulness)
   Description: A new tumor diagnosis can bring fear and uncertainty. Cognitive behavioral strategies and mindfulness can lessen anxiety, improve sleep, and help with treatment decisions. Support groups (in-person or virtual) provide community and practical tips.
   Purpose: Improve quality of life and reduce distress.
   Mechanism: Skills that calm the stress response and reframe unhelpful thoughts. Cancer.gov

6. Sexual health counseling
   Description: Hormonal shifts, surgical changes, and anxiety can affect desire, arousal, and comfort. A clinician can discuss lubricants, vaginal moisturizers, positions, and when to consider pelvic floor therapy or medical options. Partners can be included to improve communication.
   Purpose: Restore pleasurable, pain-free intimacy.
   Mechanism: Education, gradual return plans, and symptom-directed strategies. Cancer.gov

7. Exercise (aerobic + strength, tailored)
   Description: Regular activity improves fatigue, mood, and cardiometabolic health after surgery. Start with light walking and progressive resistance training under guidance if needed.
   Purpose: Boost energy, function, and long-term health; lower treatment-related fatigue.
   Mechanism: Improves cardiorespiratory fitness, muscle strength, and insulin sensitivity. Cancer.gov

8. Nutrition counseling (whole-food pattern)
   Description: Emphasize vegetables, fruits, whole grains, legumes, nuts, and lean proteins; limit ultra-processed foods, excess sugar, and alcohol. Registered dietitians can individualize plans for weight stability, bowel comfort, and iron/fiber balance post-op.
   Purpose: Support healing and overall well-being.
   Mechanism: Provides micronutrients, fiber, and balanced macros; stabilizes energy and bowel function. Cancer.gov

9. Acupuncture for postoperative symptoms
   Description: Some patients find acupuncture helps with postoperative nausea, pain, or stress; it is considered an optional, complementary therapy when performed by licensed practitioners.
   Purpose: Reduce selected symptoms and improve relaxation.
   Mechanism: Neuromodulation and endogenous endorphin release; placebo and expectancy effects may contribute. Cancer.gov

10. Quit smoking & limit alcohol
    Description: If you smoke, quitting improves wound healing and long-term health; alcohol limitation supports sleep, mood, and liver health.
    Purpose: Lower complications and improve overall outcomes.
    Mechanism: Reduces inflammation and toxins that impair recovery. Cancer.gov

11. Sleep hygiene program
    Description: Set a regular sleep schedule, limit screens before bed, and consider brief CBT-I strategies if insomnia persists. Better sleep lowers fatigue and improves coping.
    Purpose: Restore restorative sleep and daytime energy.
    Mechanism: Stabilizes circadian rhythm and lowers hyperarousal. Cancer.gov

12. Pain self-management toolkit
    Description: Combine scheduled non-opioid pain relievers (per clinician advice), heat/ice, gentle stretching, and pacing. Learn “flare plans” for activity.
    Purpose: Control discomfort while minimizing sedating medicines.
    Mechanism: Multimodal strategies reduce nociception and central sensitization. Cancer.gov

13. Body-image and scar-care support
    Description: Silicone gels/sheets, sun protection, and massage help the scar mature. Counseling addresses body-image changes after pelvic surgery.
    Purpose: Improve comfort with one’s body and scar quality.
    Mechanism: Topical occlusion and gentle remodeling of scar tissue. Cancer.gov

14. Return-to-work/role planning
    Description: A structured plan with your care team and employer (gradual hours, modified duties) eases the transition back to normal life.
    Purpose: Prevent overexertion and support recovery.
    Mechanism: Graded increase in cognitive/physical load. Cancer.gov

15. Vaccination review
    Description: Keep routine vaccines up to date (e.g., flu, COVID-19) to prevent avoidable infections during recovery.
    Purpose: Reduce illness that can delay healing or follow-up.
    Mechanism: Adaptive immunity against common respiratory pathogens. Cancer.gov

16. Genetic counseling when indicated
    Description: Some epithelial ovarian tumors associate with BRCA or other gene changes. While true LMP tumors are less often linked, a family history discussion can clarify whether testing is helpful.
    Purpose: Inform personal surveillance and family risk.
    Mechanism: Identifies inherited variants that guide future screening decisions. Cancer.gov

17. Bone health basics (if oophorectomy or low estrogen)
    Description: After removal of both ovaries, discuss calcium, vitamin D, weight-bearing exercise, and bone density testing.
    Purpose: Prevent osteoporosis over time.
    Mechanism: Supports bone remodeling and mineralization. Cancer.gov

18. Nausea minimization strategies (non-drug)
    Description: Small, frequent meals; ginger tea; acupressure bands; fresh air; and hydration can help if postoperative nausea appears.
    Purpose: Reduce nausea without extra medicines when possible.
    Mechanism: Gentle vestibular and gastric calming strategies. Cancer.gov

19. Financial navigation
    Description: Hospital social workers can help with insurance questions, medical leave, and travel assistance for care.
    Purpose: Lessen financial stress that can affect health decisions.
    Mechanism: Connects you to benefits and assistance programs. Cancer.gov

20. Reliable information sources & symptom diary
    Description: Use trustworthy, up-to-date pages (e.g., NCI PDQ) and keep a simple diary of symptoms, periods, and questions for appointments.
    Purpose: Improve visit quality and early problem-spotting.
    Mechanism: Better recall and shared decision-making. Cancer.gov

---

Drug treatments

Key safety note: Most LMP ovarian tumors are managed with surgery alone. Chemotherapy or targeted drugs are not routinely indicated and are considered only in unusual circumstances (e.g., advanced disease with invasive implants or recurrence), often using regimens from epithelial ovarian cancer. Any medicine below must be prescribed by your oncology team based on your exact pathology and situation. Cancer.gov

For each drug: ~150-word plain description + class + typical dose/time + purpose + mechanism + common side effects (from FDA labels). Doses are representative and must be individualized.

1. Carboplatin
   Description: A backbone platinum chemotherapy used widely in epithelial ovarian cancer; occasionally considered when systemic therapy is chosen for special LMP situations.
   Class: Platinum compound.
   Dose/Time: Dosed by AUC (e.g., AUC 5–6 IV every 3 weeks) when used; individualized by renal function.
   Purpose: Cytotoxic therapy to shrink or control disease if systemic therapy is needed.
   Mechanism: Cross-links DNA, blocking replication and inducing apoptosis.
   Side effects: Bone-marrow suppression (low blood counts), nausea/vomiting, taste changes, fatigue; less nephro- and neurotoxicity than cisplatin but still possible. FDA Access Data+1

2. Cisplatin
   Description: An older platinum; sometimes used in combinations historically for ovarian tumors.
   Class: Platinum compound.
   Dose/Time: Commonly 50–75 mg/m² IV every 3 weeks in combos; individualized.
   Purpose: Cytotoxic option if a platinum is used.
   Mechanism: DNA cross-linking and apoptosis.
   Side effects: Nausea/vomiting, kidney injury, neuropathy, hearing changes, low blood counts. FDA Access Data+1

3. Paclitaxel (Taxol)
   Description: Partner drug with platinum in many epithelial ovarian regimens; less typical for LMP but sometimes used if systemic therapy is chosen.
   Class: Taxane antimicrotubule agent.
   Dose/Time: 175 mg/m² IV over 3 hours every 3 weeks (classic regimen with platinum).
   Purpose: Enhance cancer cell kill with platinum.
   Mechanism: Stabilizes microtubules, halting cell division.
   Side effects: Neutropenia, hair loss, neuropathy, infusion reactions, fatigue. FDA Access Data+1

4. Docetaxel
   Description: Another taxane sometimes substituted for paclitaxel in ovarian regimens; rarely relevant to LMP but included for completeness.
   Class: Taxane antimicrotubule agent.
   Dose/Time: 60–75 mg/m² IV every 3 weeks when used in combos; individualized.
   Purpose: Alternative taxane in platinum-taxane therapy.
   Mechanism: Microtubule stabilization, mitotic arrest.
   Side effects: Neutropenia, fluid retention, nail changes, neuropathy, fatigue. FDA Access Data+1

5. Pegylated liposomal doxorubicin (DOXIL)
   Description: Liposomal anthracycline used for platinum-resistant epithelial ovarian cancer; occasionally considered in complex LMP scenarios under specialist guidance.
   Class: Anthracycline (liposomal).
   Dose/Time: 40–50 mg/m² IV every 4 weeks (varies).
   Purpose: Option in resistant settings when cytotoxic therapy is selected.
   Mechanism: Intercalates DNA, inhibits topoisomerase II, generates free radicals.
   Side effects: Hand-foot syndrome, mucositis, stomatitis, myelosuppression; cardiotoxicity risk monitored. FDA Access Data+1

6. Topotecan
   Description: A topoisomerase I inhibitor approved for metastatic ovarian cancer after progression; rarely applied to LMP.
   Class: Camptothecin topoisomerase I inhibitor.
   Dose/Time: 1.5 mg/m² IV daily for 5 days every 21 days (typical).
   Purpose: Salvage therapy in select recurrent settings.
   Mechanism: Stabilizes topoisomerase I-DNA complex causing DNA breaks.
   Side effects: Significant neutropenia/anemia, fatigue, GI upset. FDA Access Data

7. Gemcitabine
   Description: Nucleoside analog active in relapsed ovarian cancer (often with carboplatin).
   Class: Antimetabolite.
   Dose/Time: 1000 mg/m² IV on days 1 and 8 of a 21-day cycle (with carboplatin in relapse).
   Purpose: Combination option in platinum-sensitive relapse settings.
   Mechanism: Incorporates into DNA, halting replication.
   Side effects: Low blood counts, rash, liver enzyme elevations, rare lung toxicity. FDA Access Data+1

8. Bevacizumab (Avastin)
   Description: Anti-VEGF antibody used with chemotherapy and as maintenance in epithelial ovarian cancer; not standard for classic LMP but sometimes discussed in complex/recurrent scenarios.
   Class: Anti-angiogenic monoclonal antibody.
   Dose/Time: 15 mg/kg IV every 3 weeks (typical).
   Purpose: Starve tumors by blocking new blood vessel growth.
   Mechanism: Binds VEGF-A, reducing angiogenesis.
   Side effects: Hypertension, proteinuria, bleeding, rare perforation/fistula; avoid with bowel involvement or obstruction. FDA Access Data

9. Olaparib (Lynparza)
   Description: PARP inhibitor for maintenance after response to platinum in epithelial ovarian cancer and for BRCA-mutated disease; relevance to LMP is limited and off-label unless invasive carcinoma features exist.
   Class: PARP inhibitor (targeted).
   Dose/Time: 300 mg orally twice daily for maintenance (per label).
   Purpose: Prolong remission in HRD/BRCA-related epithelial ovarian cancer.
   Mechanism: Inhibits PARP-mediated DNA repair, causing synthetic lethality in HRD cells.
   Side effects: Anemia, nausea, fatigue, rare MDS/AML warning. FDA Access Data+1

10. Niraparib (Zejula)
    Description: PARP inhibitor for maintenance after response to platinum in advanced or recurrent epithelial ovarian cancer.
    Class: PARP inhibitor.
    Dose/Time: Once-daily oral dosing; individualized starting dose by weight/platelets per label.
    Purpose: Maintenance to delay recurrence in responsive disease.
    Mechanism: PARP inhibition → impaired single-strand break repair.
    Side effects: Thrombocytopenia, anemia, hypertension, nausea, fatigue. FDA Access Data+1

11. Rucaparib (Rubraca)
    Description: PARP inhibitor approved for maintenance and for BRCA-mutated recurrent epithelial ovarian cancer after multiple lines.
    Class: PARP inhibitor.
    Dose/Time: 600 mg orally twice daily (typical).
    Purpose: Maintenance or treatment in selected BRCA-mutated settings.
    Mechanism: PARP blockade leads to unrepaired DNA damage in HRD tumors.
    Side effects: Nausea, liver enzyme rises, anemia; rare MDS/AML. FDA Access Data+1

12. Albumin-bound paclitaxel (Abraxane)
    Description: A solvent-free formulation of paclitaxel; occasionally used in ovarian cancer scenarios where standard paclitaxel is not tolerated.
    Class: Taxane.
    Dose/Time: Various; e.g., 100 mg/m² weekly schedules.
    Purpose: Cytotoxic alternative when Cremophor-based paclitaxel is problematic.
    Mechanism: Microtubule stabilization.
    Side effects: Neuropathy, neutropenia, fatigue. FDA Access Data

13. Filgrastim (Neupogen)
    Description: Not an anti-tumor drug; supports white blood cells during chemo if needed.
    Class: G-CSF (growth factor).
    Dose/Time: Daily subcutaneous injections starting 24 hours after chemo (per label).
    Purpose: Reduce risk of febrile neutropenia.
    Mechanism: Stimulates neutrophil production and function.
    Side effects: Bone pain, rare splenic issues. FDA Access Data+1

14. Pegfilgrastim (Neulasta)
    Description: Long-acting G-CSF used once per cycle after chemo to maintain counts.
    Class: Pegylated G-CSF.
    Dose/Time: 6 mg subcutaneously once per chemo cycle (≥24 hours after chemo).
    Purpose: Prevent febrile neutropenia with convenient dosing.
    Mechanism: Prolonged G-CSF stimulation of neutrophils.
    Side effects: Bone pain; rare splenic rupture or ARDS warnings. FDA Access Data+1

15. Cisplatin + Paclitaxel (combination)
    Description: Historic combination for first-line epithelial ovarian cancer; rarely chosen in LMP.
    Class: Platinum + taxane.
    Dose/Time: Paclitaxel 135–175 mg/m² + cisplatin 50–75 mg/m² every 3 weeks.
    Purpose: Cytotoxic backbone when systemic therapy is clearly indicated.
    Mechanism: DNA cross-linking plus microtubule stabilization.
    Side effects: Myelosuppression, neuropathy, nausea, renal toxicity (cisplatin). FDA Access Data

16. Carboplatin + Paclitaxel (combination)
    Description: Modern standard backbone in epithelial ovarian cancer; mentioned here only to show what “standard chemo” refers to in guidelines.
    Class: Platinum + taxane.
    Dose/Time: Paclitaxel 175 mg/m² + carboplatin AUC 5–6 every 3 weeks.
    Purpose: Primary cytotoxic regimen in epithelial disease when needed.
    Mechanism: Combined DNA damage and mitotic arrest.
    Side effects: Neutropenia, neuropathy, alopecia, fatigue, nausea. FDA Access Data

17. Gemcitabine + Carboplatin
    Description: Used in platinum-sensitive relapsed epithelial ovarian cancer.
    Class: Antimetabolite + platinum.
    Dose/Time: Gemcitabine 1000 mg/m² days 1 & 8 + carboplatin day 1 every 21 days.
    Purpose: Active relapse option in epithelial disease.
    Mechanism: DNA incorporation (gemcitabine) + cross-linking (carboplatin).
    Side effects: Myelosuppression, fatigue, transaminitis. FDA Access Data

18. Topotecan (single-agent)
    Description: Salvage option after progression; included for completeness.
    Class: Topoisomerase I inhibitor.
    Dose/Time: 1.5 mg/m² IV days 1–5 q21d.
    Purpose: Later-line cytotoxic option.
    Mechanism: DNA strand break accumulation.
    Side effects: Cytopenias, fatigue, GI upset. FDA Access Data

19. Hormonal therapy (Letrozole, Tamoxifen—off-label in LMP)
    Description: Some clinicians consider endocrine therapy in select recurrent LMP cases with hormone-sensitive features; this is off-label and individualized.
    Class: Aromatase inhibitor (letrozole) or SERM (tamoxifen).
    Dose/Time: Letrozole 2.5 mg daily; Tamoxifen 20 mg daily (breast cancer dosing).
    Purpose: Attempt to slow hormonally driven growth in limited scenarios.
    Mechanism: Lowers estrogen production (letrozole) or blocks estrogen receptor (tamoxifen).
    Side effects: Joint pain/hot flashes (letrozole), thromboembolism/endometrial effects (tamoxifen). FDA Access Data+1

20. Bevacizumab + PARP inhibitor maintenance (select epithelial cases)
    Description: In HRD-positive advanced epithelial ovarian cancer after response to first-line therapy, olaparib + bevacizumab is an FDA-labeled option; this is not standard for classic LMP and is included only to outline the epithelial landscape.
    Class: PARP inhibitor + anti-VEGF.
    Dose/Time: Olaparib 300 mg BID orally + bevacizumab 15 mg/kg IV q3w (per label).
    Purpose: Maintain remission in HRD-positive epithelial disease.
    Mechanism: DNA repair inhibition + anti-angiogenesis.
    Side effects: From each agent as above (anemia, hypertension, etc.). FDA Access Data

---

Dietary molecular supplements

Evidence for supplements in LMP tumors is limited. Focus on food first. If you consider a supplement, discuss interactions with your clinician.

1. Omega-3 (EPA/DHA)
   Long description (≈150 words): Marine omega-3s may help general inflammation control and support cardiovascular health during recovery. Typical trial doses range 1–2 grams/day combined EPA/DHA. Choose a third-party tested product to avoid contaminants. Omega-3s can mildly thin blood; tell your surgeon and oncologist before procedures.
   Dose: 1–2 g/day EPA+DHA (example).
   Function/Mechanism: Modulates eicosanoids and inflammatory pathways.

2. Vitamin D3
   Description: Helps bone health if ovarian hormones fall after surgery; deficiency is common. Have levels checked and supplement only to reach normal range.
   Dose: Personalized (often 800–2000 IU/day; higher if deficient under supervision).
   Function/Mechanism: Regulates calcium/phosphate balance; supports bone remodeling.

3. Calcium (if intake is low)
   Description: Use food sources first; supplement only if dietary intake is inadequate, especially after oophorectomy.
   Dose: Typically to reach ~1000–1200 mg/day total intake.
   Function/Mechanism: Mineral for bone density.

4. Probiotic (selected strains)
   Description: May aid bowel regularity after surgery and antibiotics; pick clinically studied strains and start low.
   Dose: As per product.
   Function/Mechanism: Microbiome support and short-chain fatty acid production.

5. Ginger extract
   Description: Can help nausea and mild dyspepsia for some people.
   Dose: Up to ~1 g/day divided (capsules or tea); watch for reflux.
   Function/Mechanism: 6-gingerol/6-shogaol may influence gastric motility.

6. Curcumin (turmeric extract)
   Description: Anti-inflammatory properties in general wellness literature; discuss anticoagulants/bleeding risk before use.
   Dose: 500–1000 mg/day standardized extract (with food/pepperine for absorption), if approved.
   Function/Mechanism: Inhibits NF-κB and other inflammatory mediators.

7. Green tea extract (EGCG)
   Description: Antioxidant polyphenols; may cause GI upset or interact with some medicines.
   Dose: Per label; avoid high doses near surgery.
   Function/Mechanism: Polyphenol-mediated antioxidant effects.

8. Magnesium (if low or constipated)
   Description: Supports bowel regularity and sleep; excess can cause diarrhea.
   Dose: 200–400 mg at night (varies).
   Function/Mechanism: Smooth muscle relaxation; cofactor in many enzymes.

9. B-complex (food-first; supplement if deficient)
   Description: Helps energy metabolism; consider only for documented deficiency or inadequate diet.
   Dose: As labeled.
   Function/Mechanism: Cofactors in cellular energy pathways.

10. Protein powder (whey or plant)
    Description: Useful short-term if appetite is low post-op; prioritize whole foods first.
    Dose: Enough to reach ~1.0–1.2 g/kg/day protein (typical recovery targets).
    Function/Mechanism: Provides amino acids for healing.

(Dietary supplement evidence for LMP specifically is limited; prioritize food patterns and clinician-guided use.) Cancer.gov

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved stem-cell drugs to treat LMP ovarian tumors. Be cautious about any clinic offering “stem-cell” cures. The only “immune-support” medicines used around chemotherapy are growth factors that restore white blood cells; they do not treat the tumor itself. Below are legitimate supportive agents and clarifications. Cancer.gov

1. Filgrastim (Neupogen)
   Description (≈100 words): Short-acting G-CSF that increases neutrophils after chemo.
   Dose: Daily SC injections as directed, starting ≥24 hours after chemo.
   Function/Mechanism: Stimulates bone marrow to produce neutrophils.
   Mechanism detail: G-CSF receptor signaling → proliferation and maturation of neutrophil precursors. FDA Access Data

2. Pegfilgrastim (Neulasta)
   Description: Long-acting G-CSF given once per cycle after chemo to prevent febrile neutropenia.
   Dose: 6 mg SC once per chemo cycle (timing per label).
   Function/Mechanism: Sustained neutrophil support via pegylated G-CSF. FDA Access Data

3. Vaccinations (e.g., influenza, COVID-19)
   Description: Reduce risk of serious infections during recovery; schedule timing around major procedures per clinician guidance.
   Dose: Per public health schedule.
   Function/Mechanism: Induces adaptive immune memory. Cancer.gov

4. Nutrition & exercise (physiology-based “immune support”)
   Description: Adequate protein, micronutrients, and regular moderate activity support normal immune function.
   Dose: Lifestyle prescription; not a drug.
   Function/Mechanism: Supports leukocyte function, reduces chronic inflammation. Cancer.gov

5. Sleep optimization
   Description: Good sleep hygiene improves immune signaling and recovery.
   Dose: 7–9 hours/night with consistent timing.
   Function/Mechanism: Restores circadian immune rhythms. Cancer.gov

6. Avoid unapproved stem-cell therapies
   Description: Unregulated treatments can be unsafe and ineffective. Discuss clinical trials with your oncologist instead.
   Function/Mechanism: Safety through evidence-based care and regulated research pathways. Cancer.gov

---

Surgeries

1. Unilateral salpingo-oophorectomy (USO)
   Procedure: Removal of the ovary and fallopian tube on the affected side.
   Why: Standard for many early LMP tumors in people desiring future fertility; removes tumor while preserving the other ovary and the uterus. Cancer.gov

2. Cystectomy (ovarian cyst removal)
   Procedure: Removes only the cyst/tumor, leaving as much normal ovary as possible.
   Why: Option for very select, small, well-defined LMP tumors with a strong desire to preserve fertility; requires close follow-up. Cancer.gov

3. Bilateral salpingo-oophorectomy (BSO)
   Procedure: Removes both ovaries and tubes.
   Why: Considered when childbearing is complete, when disease involves both ovaries, or when risk reduction is preferred. Cancer.gov

4. Comprehensive surgical staging
   Procedure: Careful inspection of the abdomen/pelvis, peritoneal washings, biopsies, and sometimes omentectomy.
   Why: Confirms stage, detects implants, and guides need for any further care. Cancer.gov

5. Completion surgery
   Procedure: After fertility is achieved or when risk-benefit shifts, the remaining ovary/tube (and sometimes uterus) may be removed.
   Why: Reduces future recurrence risk in selected cases. Cancer.gov

---

Preventions

1. Do regular gynecologic visits and follow the surveillance plan your team recommends. Cancer.gov

2. Know and act on new symptoms (bloating, pelvic pain, early fullness, changes in periods). Cancer.gov

3. Do not smoke; seek help to quit if you do. Cancer.gov

4. Maintain a healthy, whole-food dietary pattern and steady weight. Cancer.gov

5. Stay physically active most days of the week. Cancer.gov

6. Keep vaccinations current (especially flu/COVID-19). Cancer.gov

7. Manage stress with mindfulness or counseling to improve sleep and coping. Cancer.gov

8. Discuss family history; consider genetic counseling if indicated. Cancer.gov

9. Use reliable medical sources (like NCI PDQ) for information; avoid unregulated treatments. Cancer.gov

10. Follow pre- and post-operative instructions carefully to reduce complications. Cancer.gov

---

When to see a doctor urgently

Contact your care team right away if you have any of the following: new or worsening pelvic/abdominal pain, severe bloating or rapidly increasing girth, vomiting that won’t stop, fever or chills, vaginal bleeding that is heavy or unexpected, leg swelling or calf pain, chest pain or shortness of breath, or any new, persistent symptom that worries you. These symptoms may be unrelated—or signal a complication or recurrence—and are safest evaluated promptly. Cancer.gov

---

What to eat and what to avoid

What to eat :

1. Plenty of vegetables and fruits daily (aim for color variety).

2. Whole grains and legumes for fiber and steady energy.

3. Lean proteins (fish, poultry, tofu, beans) to support healing.

4. Healthy fats (olive oil, nuts, seeds).

5. Enough fluids (mostly water) to stay hydrated. Cancer.gov

What to limit/avoid :

1. Ultra-processed foods high in added sugars.

2. Excess alcohol.

3. Large amounts of red/processed meats.

4. Smoking and nicotine products.

5. High-dose supplements without clinician guidance (risk of interactions). Cancer.gov

---

Frequently asked questions (FAQs)

1. Is an LMP ovarian tumor “cancer”?
   No. It has abnormal cells with borderline features but lacks destructive invasion seen in cancer. Outcomes are generally excellent, especially with early, complete surgery. Cancer.gov

2. Do I always need chemotherapy?
   Usually no. Most LMP tumors are treated with surgery alone. Chemo or targeted drugs are reserved for unusual, advanced, or recurrent scenarios and decided by a gynecologic oncologist. Cancer.gov

3. Can I keep my fertility?
   Often yes. Many people have fertility-sparing surgery with careful follow-up. Discuss your goals before surgery. Cancer.gov

4. How often will I need check-ups after surgery?
   Your team will create a schedule of pelvic exams and imaging at set intervals, adjusting over time. Cancer.gov

5. Are blood tests like CA-125 reliable for LMP?
   They may be used selectively, but they’re less useful than in invasive ovarian cancer; imaging and exams matter more. Cancer.gov

6. What if my pathology says “implants”?
   Your surgeon will explain whether implants are non-invasive or invasive; this influences staging, prognosis, and surveillance intensity. Cancer.gov

7. Do PARP inhibitors (like olaparib) apply to LMP?
   They are approved for epithelial ovarian cancer scenarios (e.g., maintenance after platinum response, BRCA/HRD-positive disease), but not standard for classic LMP. FDA Access Data

8. Is bevacizumab (Avastin) used for LMP?
   It’s used in epithelial ovarian cancer; for LMP it’s not routine and would be considered only in special circumstances and clinical trials. FDA Access Data

9. Do growth-factor shots treat the tumor?
   No. Agents like filgrastim or pegfilgrastim only help white blood cells recover during chemo; they don’t kill tumor cells. FDA Access Data+1

10. Are there approved stem-cell treatments for LMP ovarian tumors?
    No. Avoid unregulated “stem-cell” clinics; ask about legitimate clinical trials if interested. Cancer.gov

11. What lifestyle steps help recovery?
    Regular activity, whole-food nutrition, good sleep, and stress-reduction improve energy and well-being after surgery. Cancer.gov

12. Will I need hormone therapy?
    Hormone therapy isn’t standard for LMP, though endocrine drugs are sometimes tried off-label for select recurrences. Discuss risks and benefits with your oncologist. FDA Access Data+1

13. How long is follow-up needed?
    Your team will outline a multi-year plan since late recurrences are uncommon but possible; schedules are individualized. Cancer.gov

14. What warning signs should I never ignore?
    New or worsening abdominal/pelvic pain, severe bloating, vomiting, fever, heavy bleeding, chest pain, or shortness of breath—seek care promptly. Cancer.gov

15. Where can I read reliable, up-to-date information?
    Start with the NCI PDQ pages on ovarian borderline tumors (patient and professional versions). Cancer.gov+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.